Greg Freiherr, Industry Consultant
Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | February 03, 2014

Nuc Med Promises HIV Cure

My generation has seen the rise of a frightening kind of STD, one that was unflinchingly lethal early on and since has been unrelenting, if survivable. Today AIDS is managed, not cured, the lethality of its cause, HIV, held at bay with a cocktail of daily medications. But now there is hope for a cure: radioimmunotherapy (RIT) promises the destruction of HIV-infected cells and the means to verify it.

Researchers at Albert Einstein College of Medicine have used RIT to kill cells infected with HIV. They were destroyed in the blood samples of patients treated with a retroviral antibody. Optimism rising from the in vitro work has been bolstered by in vivo studies on mice, according to Ekaterina (Kate) Dadachova, Ph.D., who says clinical studies are scheduled to begin soon. “Our research showed that RIT is able to kill HIV-infected cells both systemically and within the central nervous system,” said Dadachova, a professor of radiology, microbiology and immunology at Albert Einstein College of Medicine at Yeshiva University.

The experimental therapy may vanquish the HIV infection within the patient, she said, just as the radioactive element of the RIT – 213-bismuth – allows SPECT to track its march to HIV infected cells. Dadachova plans to use SPECT imaging to track the RIT in a clinical trial set to begin later this year in collaboration with the University of Pretoria in South Africa.

This shot at a cure may be coming none too soon. Increasingly virulent strains of HIV are showing up around the world. They are recombinants created when a person becomes infected with two different strains that fuse into a novel and more virulent form. Exemplifying the danger of such recombination is a form discovered and reported last year by Lund University in Sweden. Called A3/02, it is a cross between the two most common strains in Guinea-Bissau, West Africa — 02AG and A3.

This new strain has been found so far only in West Africa. But research has determined that recombinants are spreading globally at an increasing rate. Particularly susceptible are countries with high levels of immigration, such as the United States and Europe.

RIT is not a cure in itself but one that holds promise when used in concert with highly active antiretroviral therapy (HAART). Widely used to treat HIV-infected patients, HAART suppresses viral replication. But, while reducing the burden of HIV, reservoirs of latently infected cells are believed to persist in the body.

"HAART cannot kill the HIV-infected cells,” Dadachova said. RIT might.

In the research, Dadachova and her team administered RIT to blood samples from 15 HIV patients treated with HAART at the Einstein-Montefiore Center for AIDS Research. The preliminary research showed the RIT killed HIV-infected lymphocytes previously treated with HAART, reducing the HIV infection in the blood samples to undetectable levels. “The elimination of HIV-infected cells with RIT was profound and specific,” she said. “The radionuclide we used delivered radiation only to HIV-infected cells without damaging nearby cells.”

The RIT uses a type of monoclonal antibody (mAb2556) paired with bismuth radioisotope. When injected into the patient's bloodstream, the combination is expected to travel to the HIV-infected cell, which should then be destroyed by the radiation.

Raising expectations that there will be no refuge for HIV, Dadachova and her team have demonstrated that the radiolabeled antibody can cross the human blood brain barrier to reach HIV-infected cells in the brain and central nervous system. “Antiretroviral treatment only partially penetrates the blood brain barrier, which means that even if a patient is free of HIV systemically, the virus is still able to rage on in the brain, causing cognitive disorders and mental decline,” she said. “Our study showed that RIT is able to kill HIV-infected cells both systemically and within the central nervous system.”

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...